-
Product Insights
NewVentilator Associated Pneumonia (VAP) – Drugs In Development, 2024
Empower your strategies with our Ventilator Associated Pneumonia (VAP) – Drugs In Development, 2024 report and make more profitable business decisions. Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in...
-
Product Insights
NewBurkholderia Infections – Drugs In Development, 2024
Empower your strategies with our Burkholderia Infections – Drugs In Development, 2024 report and make more profitable business decisions. Burkholderia is a genus of Pseudomonadota whose pathogenic members include the Burkholderia cepacia complex, which attacks humans and Burkholderia mallei, responsible for glanders, a disease that occurs mostly in horses and related animals; Burkholderia pseudomallei, causative agent of melioidosis; and Burkholderia cepacia, an important pathogen of pulmonary infections in people with cystic fibrosis (CF). The Burkholderia Infections drugs in development market research...
-
Product Insights
NewCystic Fibrosis – Drugs In Development, 2024
Empower your strategies with our Cystic Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose, and severe constipation. Risk factors include family history and race (Northern...
-
Product Insights
NewRespiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024
Empower your strategies with our Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Respiratory syncytial virus (RSV) infection is a respiratory disease. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache, and fever. Treatment includes proper medication and hygiene practice. The Respiratory Syncytial Virus...
-
Product Insights
NewAcinetobacter Infections – Drugs In Development, 2024
Empower your strategies with our Acinetobacter Infections – Drugs In Development, 2024 report and make more profitable business decisions. Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, or urinary tract). Symptoms include fever and red, swollen, warm, or painful skin areas or wounds. Predisposing factors include weak immune system, poor hygiene, and recent surgery or procedure. The Acinetobacter Infections drugs in...
-
Product Insights
Histology And Cytology Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Histology and Cytology Pipeline Market Report Overview Histology and Cytology consist of reagents and test kits used in tissue and cell typing techniques. Reagents like monoclonal antibodies, polyclonal antibodies, immunomodulators, and tissue typing reagents have been tracked under this category in the report. Apart from reagents flow cytometry reagents are also tracked. The Histology and Cytology pipeline market research report provides comprehensive information about the Histology and Cytology pipeline products with a comparative analysis of the products at various stages...
-
Product Insights
NewNet Present Value Model: Xencor Inc’s Vibecotamab
Empower your strategies with our Net Present Value Model: Xencor Inc's Vibecotamab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Aridis Pharmaceuticals Inc’s Suvratoxumab
Empower your strategies with our Net Present Value Model: Aridis Pharmaceuticals Inc's Suvratoxumab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Iterum Therapeutics Plc’s Sulopenem Etzadroxil
Empower your strategies with our Net Present Value Model: Iterum Therapeutics Plc's Sulopenem Etzadroxil report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Aridis Pharmaceuticals Inc’s Aerumab
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.